DOAC

AcronymDefinition
DOACDirect Oral Anticoagulant (medical treatment)
DOACDark Age of Camelot (game)
DOACDescription of a Career
DOACDenwood Outdoor Athletics Club (Canada)
DOACDelaware Outdoor Adventure Center
DOACDefence Operational Analysis Centre (UK)
DOACDownsview Orthopaedic & Arthrtis Centre (Canada)
DOACDamaging Or Altering Computers
DOACData Operations and Analysis Center
References in periodicals archive ?
One thing to consider is that studies demonstrating interaction between the DOAC and AED drug classes have been performed in healthy volunteers, making it difficult to extrapolate how this interaction may increase the risk for thrombotic events in other patients.
6) Patients taking such agents could theoretically have decreased exposure to the DOAC, resulting in an increase in thromboembolic risk.
9] With the introduction of new DOACs it will be important to obtain baseline data on VTE prevalence, diagnosis and treatment in order to evaluate the benefit of these anticoagulants in an era of high HIV and TB prevalence and incidence.
Furthermore, DOAC require measurement of their anticoagulant effect in special situations (50).
This kind of 'less is more' approach includes avoiding prescribing DOACs rather than VKAs without clear, compelling, evidence-based reasons; regularly reassessing renal function; monitoring for adverse effects; and reappraising aspirin prescription.
The HemosIL Rivaroxaban Testing Solution is the second assay IL has commercialised in the company's DOAC Assay Panel, following the introduction of their HemosIL Direct Thrombin Inhibitor Assay for measurement of dabigatran (Pradaxa) in September 2014.
Clinical situations in which the measurement of DOAC anticoagulant activity is potentially useful When stable anticoagulation is achieved (1-2 weeks after initiation) Before surgical or other invasive procedures Adverse events (haemorrhage or thrombosis) Before and after introducing additional drugs which are known to interact Extremes of body mass index Suspected overdose When bridging from one anticoagulant to another To assess compliance To exclude drug accumulation in the elderly To assess pharmacological activity, i.
The incidence of ischemic stroke or systemic embolism was either the same or better for each of the 3 DOAC treatments than for warfarin (DOACs, 2.
A meta-analysis of the 4 phase III trials of the DOACs, this time involving 58,338 patients, evaluated DOAC efficacy and safety compared to warfarin in the presence of kidney dysfunction.
As the only Japanese pharmaceutical company who has developed and launched a DOAC product globally, Daiichi Sankyo is committed to contributing to the health of Japanese elderly NVAF patients.
DOACs are at least as effective as warfarin at preventing stroke in patients with atrial fibrillation and may even be safer.